HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintained an $18 price target.
October 09, 2023 | 10:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Tenaya Therapeutics and maintained an $18 price target.
The reiteration of a 'Buy' rating and maintenance of an $18 price target by HC Wainwright & Co. is a positive signal for Tenaya Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100